We serve Chemical Name:5-Phenylnorvaline CAS:36061-08-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-Phenylnorvaline
CAS.NO:36061-08-2
Synonyms:Benzenepentanoic acid, α-amino-;(2R)-2-amino-5-phenylpentanoic acid;2-amino-5-phenylpentanoic acid;5-Phenylnorvaline
Molecular Formula:C11H15NO2
Molecular Weight:193.242
HS Code:2922499990
Physical and Chemical Properties:
Melting point:N/A
Boiling point:375.2±42.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.556
PSA:63.32000
Exact Mass:193.110275
LogP:1.81
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Benzenepentanoic acid, α-amino- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Phenylnorvaline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzenepentanoic acid, α-amino- Use and application,2-amino-5-phenylpentanoic acid technical grade,usp/ep/jp grade.
Related News: The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 5-Phenylnorvaline manufacturer The government will also send a charter flight with an Air New Zealand crew to repatriate up to 300 citizens in Wuhan. 5-Phenylnorvaline supplier At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival. 5-Phenylnorvaline vendor The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 5-Phenylnorvaline factory The government will also send a charter flight with an Air New Zealand crew to repatriate up to 300 citizens in Wuhan.
